Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11271192 | 0.98 | MAPT (0.59) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL1608919 | 0.84 | SMN1; SMN2 (0.61) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL11070595 | 0.84 | MAPT (0.59) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL4705798 | 0.82 | MEN1 (0.46) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL10919482 | 0.81 | MAPT (0.53) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL10917670 | 0.81 | CYP1A2 (0.64) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL11270696 | 0.81 | MAPT (0.53) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL38664509 | 0.81 | PKM (0.54) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL10920509 | 0.79 | SMN1; SMN2 (0.42) | MAPTPKMCYP1A2POLBBLM | |
| SCHEMBL11277126 | 0.79 | POLB (0.52) | MAPTPKMCYP1A2POLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240002380-A1 | REV-ERB AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4228632-A2 | REV-ERB AGONISTS | Saint Louis University (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116635029-A | REV-ERB agonists | 圣路易斯大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022093552-A2 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093552-A2 | REV-ERB AGONISTS | Saint Louis Univeristy (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-0023707-B1 | SUBSTITUTED TETRAAZATRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-04-30 | — | — | EP | disclosed |
| EP-0066774-B1 | 1,4,9,10-TETRAHYDROPYRAZOLO(4,3-E)PYRIDO(3,2-B)(1,4)DIAZEPIN-10-ONES, PROCESS FOR THEIR PREPARATION AND MEDICINAL PREPARATIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-12-12 | — | — | EP | disclosed |
| US-4381303-A | 1,4,9,10-Tetrahydro-pyrazolo [4,3-]pyrido[-3,2-b][1,4]diazepin-10-ones | DR. KARL THOMAE GMBH (DE) | 1983-04-26 | — | — | US | disclosed |
| EP-0066774-A1 | 1,4,9,10-Tetrahydropyrazolo(4,3-e)pyrido(3,2-b)(1,4)diazepin-10-ones, process for their preparation and medicinal preparations containing them | Dr. Karl Thomae GmbH (DE) | 1982-12-15 | — | — | EP | disclosed |
| EP-0064775-A1 | Substituted tetraazatricyclic compounds, process for their preparation and their use | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-11-17 | — | — | EP | disclosed |
| US-4317823-A | FOR TREATMENT OF GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-03-02 | — | — | US | disclosed |
| EP-0023707-A1 | Substituted tetraazatricyclic compounds, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
| US-3939161-A | ANTIINFLAMMATORY, ANTISECRETORY | ABBOTT LABORATORIES (US) | 1976-02-17 | — | — | US | disclosed |
| US-3934018-A | 4,6-Dihydro-1,3-dimethyl-8-phenylpyrazolo[4,3-e] [1,4]diazepin-5-(1H)-one and derivatives as anti-inflammatory agents | ABBOTT LABORATORIES (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | MAPT 2507/4885PKM 1739/4885CYP1A2 191/4885 |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | MAPT 2314/4885PKM 592/4885CYP1A2 14/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | MAPT 1341/4885PKM 359/4885CYP1A2 1645/4885 |
| US-20240002380-A1 | REV-ERB AGONISTS | NR1D1, ESRRA, ESRRB | MAPT 1634/4885PKM 1399/4885CYP1A2 2620/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | MAPT 2314/4885PKM 592/4885CYP1A2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.